MINNEAPOLIS, May 17, 2017 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq:TCMD), a leader in developing and marketing at-home therapy devices that treat lymphedema and chronic venous insufficiency, today announced its Flexitouch® system will be available throughout the United States to treat lymphedema of the head and neck, a common consequence of head and neck cancer and related treatment, making it the first and only pneumatic compression therapy approved for this condition.
Following its U.S. Food and Drug Administration (FDA) clearance in September 2016, Tactile Medical completed a limited market release including more than 80 patients with lymphedema of the head and neck. Of the patients who tried the device, 88 percent saw a reduction in head and neck swelling after an initial 32-minute at-home treatment with the Flexitouch system, and 89 percent of patients reported improvement in other symptoms including increased ability to swallow, improved range of motion, a reduction in fibrotic (hardened) tissue and less discomfort.
“We are thrilled with these positive results demonstrating that the Flexitouch system can help head and neck lymphedema patients effectively reduce lymphedema swelling and improve their quality of life,” said Gerald R. Mattys, Chief Executive Officer of Tactile Medical. “The Flexitouch system has helped tens of thousands of patients achieve better health and manage lymphedema symptoms in their extremities. Now, for the first time, we can extend the benefits of Flexitouch to every area of the body.”
The Flexitouch system is the only pneumatic compression system clinically proven to stimulate the lymphatic system2, delivering a non-invasive therapy that patients can administer themselves.
“We have been encouraged to hear that many patients are able to feel a substantial difference in their condition after just one treatment,” said Mattys. “With very few treatment options available for these patients, we are extremely gratified that we can now extend the benefits of our Flexitouch system to patients suffering from head and neck lymphedema and help them better manage their condition at home.”
Lymphedema is a chronic disease in which excess fluid accumulates in areas of the body when lymphatic vessels do not work efficiently or have been damaged. This chronic disease affects over five million people in the United States. More than 75 percent of head and neck cancer patients experience lymphedema symptoms.1 While lymphedema is an incurable, chronic, and progressive condition, it can be effectively managed to relieve symptoms and lower the risk of skin damage and infection, reducing overall healthcare costs.
To learn more about Tactile Medical and the Flexitouch system please visit TactileMedical.com.
About Tactile Medical
Tactile Medical is a leader in developing and marketing at-home therapy devices that treat lymphedema and chronic venous insufficiency. Our unique offering includes advanced, clinically proven pneumatic compression devices, as well as continuity of care services provided by a national network of product specialists and trainers, reimbursement experts, patient advocates, and clinical staff. This combination of products and services ensures that tens of thousands of patients annually receive the at-home treatment necessary to better manage their chronic conditions. Tactile Medical takes pride in the fact that our efforts help increase clinical efficacy, reduce overall healthcare costs and improve the quality of life for patients with chronic conditions.
Legal Notice Regarding Forward-Looking Statements:
This release contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of the Company’s control that can make such statements untrue, including, but not limited to, the adequacy of the Company’s liquidity to pursue its complete business objectives; the Company’s ability to obtain reimbursement from third party payers for its products; loss or retirement of key executives; adverse economic conditions or intense competition; loss of a key supplier; entry of new competitors and products; adverse federal, state and local government regulation; technological obsolescence of the Company’s products; technical problems with the Company’s research and products; the Company’s ability to expand its business through strategic acquisitions; the Company’s ability to integrate acquisitions and related businesses; price increases for supplies and components; and the inability to carry out research, development and commercialization plans. In addition, other factors that could cause actual results to differ materially are discussed in the Company’s filings with the SEC, including the final prospectus for the Company’s initial public offering. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company undertakes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
1 Ridner, SH, Dietrich, MS, Niermann, K, Cmelak, A, Mannion, K, Murphy, B. A Prospective Study of the Lymphedema and Fibrosis Continuum in Patients with Head and Neck Cancer. Lymphatic Research and Biology. December 2016 (Vol 14/No 4).
2 Adams KE, Rasmussen JC, Darne C, Tan I, Aldrich MB, Marshall MV, Fife CE, Maus EA, Smith LA, Guilloid R, Hoy S, Sevic-Muraca EM. Direct Evidence of Lymphatic Function Improvement After Advanced Pneumatic Compression Device Treatment of Lymphedema. Biomedical Optics Express. August 2010 (Vol 1/No 1).